Abstract:Proc Amer Assoc Cancer Res, Volume 47, 2006 4662 Hepatocellular carcinoma (HCC) is one of the most common and lethal solid tumors in the world. HCC is typically refractory to almost all cytotoxic chemotherapeutic agents. OSU-03012 is a derivative of celecoxib, a cyclooxygenase (COX)-2 inhibitor. However, its primary mechanism of action is known as 3-phosphoinositide-dependent kinase-1 (PDK-1) inhibition and by which it induces apoptosis in certain cancer cells[Zhu J et al. , Cancer Res. 64:4309-18, 2004; Hsu AL et al. , J Biol. Chem . 275:11937-403. 2000]. This study sought to investigate if OSU-03012 may be effective in the treatment of HCC. OSU-03012 inhibited cell growth of Huh7, a human HCC cell line, in a dose-dependent manner, with IC50 at 1μM, which is well below the non-toxic serum concentration (5-20μM) in mice. Surprisingly, in this Huh7 cell model, western blotting analysis demonstrated that neither pPDK1 nor pAkt was suppressed by OSU-03012. Cell cycle analysis by flow cytometry indicated that OSU-03012 (5μM, 24h) significantly increased S-phase population, while did not alter sub-G1 population, suggesting that apoptosis is not a major mechanism of cell growth suppression. Western blotting analysis showed that OSU-03012 reduced protein level of cyclin D1. Furthermore, OSU-03012-treated cells exhibited cytoplasmic vacuoles which were positively stained by acridine orange and monodansylcadaverine, a phenomenon mimicking cell autophagy. The content in the OSU-03012-induced autophagosomes and its mechanistic linkage with the occurrence of autophagy-like cell death of Huh7 cells are under investigation. Together, our preliminary results indicate that OSU-03012 might be an effective therapeutic agent for HCC, but the mechanisms of action of this drug in HCC cells need to be further clarified. (This study was supported by grant DOH94-TD-B-111-001 from Department of Health, R.O.C. to National Clinical Research Center at National Taiwan University)

U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways.

Synthesis and Anti-Hepatoma Activities of U12 Derivatives Arresting G0/G1 Phase and Inducing Apoptosis by PI3K/AKT/mTOR Pathway

URD12: A urea derivative with marked antitumor activities.

Osu-03012, A Novel Celecoxib Derivative, Induces A Unique Autophagy-Like Cell Death In Human Hepatocellular Carcinoma Cells

Anti-hepatocellular carcinoma activity and mechanism of chemopreventive compounds: ursolic acid derivatives.

Osu-03012, A Novel Celecoxib Derivative, Induces Reactive Oxygen Species-Related Autophagy In Hepatocellular Carcinoma

Antitumor Agents 295. E-ring Hydroxylated Antofine and Cryptopleurine Analogues As Antiproliferative Agents: Design, Synthesis, and Mechanistic Studies.

Ursolic Acid Derivative UA232 Promotes Tumor Cell Apoptosis by Inducing Endoplasmic Reticulum Stress and Lysosomal Dysfunction

Ursolic acid induces doxorubicin-resistant HepG2 cell death via the release of apoptosis-inducing factor

Effects of Ursodeoxycholic Acid on Intrahepatic Cholestasis in Rats

Ursodeoxycholic Acid (UDCA) Increases Lactate Clearance and Reduces Liver Injury by Inhibiting Farnesoid X Receptor (FXR) in Hemorrhagic Shock (HS)

Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: Role of repressing glycolysis via miR-199a:HK2/PKM2 modulation.

Delivery of Mitogen-Activated Protein Kinase Inhibitor for Hepatocellular Carcinoma Stem Cell Therapy.

Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy

8u, a pro-apoptosis/cell cycle arrest compound, suppresses invasion and metastasis through HSP90α downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells

Substituted indole derivatives as UNC-51-like kinase 1 inhibitors: Design, synthesis and anti-hepatocellular carcinoma activity

Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells

Therapeutic Potential of CUDC-907 (fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening

C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma

Uridine Inhibits Hepatocellular Carcinoma Cell Development by Inducing Ferroptosis

Design, Synthesis, and In Vitro/In Vivo Anti-Cancer Activities of Novel (20S)-10,11-Methylenedioxy-Camptothecin Heterocyclic Derivatives